NasdaqGS - Nasdaq Real Time Price USD

Acumen Pharmaceuticals, Inc. (ABOS)

3.6900

+0.3300

(+9.82%)

At close: May 14 at 4:00 PM EDT

3.7000

+0.01

(+0.27%)

After hours: May 14 at 7:48 PM EDT

Key Events

Loading Chart for ABOS

9/21 12:03 PM

DELL

Previous Close 3.3600
Open 3.5900
Bid 3.6600 x 200
Ask 3.7200 x 100
Day's Range 3.5000 - 3.7400
52 Week Range 1.8100 - 11.3100
Volume 230,405
Avg. Volume 315,814
Market Cap (intraday) 221.694M
Beta (5Y Monthly) 0.19
PE Ratio (TTM) --
EPS (TTM) -1.0800
Earnings Date Aug 8, 2024 - Aug 12, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 12.80

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

acumenpharm.com

51

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ABOS

3.91%

S&P 500

10.00%

1-Year Return

ABOS

34.11%

S&P 500

27.22%

3-Year Return

ABOS

--

S&P 500

21.45%

5-Year Return

ABOS

--

S&P 500

21.45%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Acumen Pharmaceuticals, Inc.

3.6900

+9.82%

Mkt Cap 221.694M

Industry Biotechnology

Eledon Pharmaceuticals, Inc.

2.3400

+6.85%

Mkt Cap 88.741M

Industry Biotechnology

Immuneering Corporation

1.6000

+0.63%

Mkt Cap 47.445M

Industry Biotechnology

Autolus Therapeutics plc

3.9300

-2.00%

Mkt Cap 1.066B

Industry Biotechnology

Fennec Pharmaceuticals Inc.

7.34

-26.75%

Mkt Cap 271.755M

Industry Biotechnology

Inozyme Pharma, Inc.

4.6300

+2.66%

Mkt Cap 286.391M

Industry Biotechnology

Jasper Therapeutics, Inc.

20.92

+0.77%

Mkt Cap 315.591M

Industry Biotechnology

Aerovate Therapeutics, Inc.

19.28

+0.73%

Mkt Cap 554.057M

Industry Biotechnology

Cellectar Biosciences, Inc.

3.1800

+3.92%

Mkt Cap 114M

Industry Biotechnology

4.8200

-1.03%

Mkt Cap 443.858M

Industry Biotechnology

Achilles Therapeutics plc

0.9200

+3.94%

Mkt Cap 37.998M

Industry Biotechnology

Valuation Measures

As of 5/13/2024

Market Cap

201.87M
Enterprise Value

-13.17M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

0.76
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-15.08%
Return on Equity (ttm)

-22.98%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

-52.37M
Diluted EPS (ttm)

-1.0800

Balance Sheet and Cash Flow

Total Cash (mrq)

243.52M
Total Debt/Equity (mrq)

11.63%
Levered Free Cash Flow (ttm)

-28.24M

ABOS does not have Company Insights

AVTE Aerovate Therapeutics, Inc.

19.28

+0.73%

LVTX LAVA Therapeutics N.V.

2.8900

-5.56%

TNYA Tenaya Therapeutics, Inc.

4.4000

+2.80%

DAWN Day One Biopharmaceuticals, Inc.

16.62

+3.55%

ABSI Absci Corporation

4.8300

-4.55%

VTYX Ventyx Biosciences, Inc.

4.1700

+1.21%

TSHA Taysha Gene Therapies, Inc.

2.5700

+7.08%

ALXO ALX Oncology Holdings Inc.

15.17

-2.82%

BMEA Biomea Fusion, Inc.

12.37

+8.03%

ANNX Annexon, Inc.

4.8200

-1.03%

INAB IN8bio, Inc.

1.0400

+2.97%

ELEV Elevation Oncology, Inc.

3.5600

+0.56%

GLUE Monte Rosa Therapeutics, Inc.

5.0000

+1.01%

HOWL Werewolf Therapeutics, Inc.

4.9300

+10.54%

GBIO Generation Bio Co.

3.5400

+24.65%

ACXP Acurx Pharmaceuticals, Inc.

2.0900

+0.97%